Of significance, diminished responses of ICI or ADCs have been documented in a majority of NSCLC patients having driver mutations or alterations in oncogenes, including EGFR, ALK, ROS1[37,38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.